Stanley H. Hsia

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

W. Timothy Garvey, Stanley H. Hsia, Thomas C. Jones · The Lancet · 2023 · 687 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +10

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 642 citations

Medicine, Pharmacology, Pharmacotherapy +16

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

Paresh Dandona, Pieter Gillard, Peter Senior et al. · Diabetes Care · 2018 · 252 citations

Medicine, Pharmacology, Pharmacotherapy +15

The Effects of Varying Doses of T on Insulin Sensitivity, Plasma Lipids, Apolipoproteins, and C-Reactive Protein in Healthy Young Men

Atam B. Singh, Stanley H. Hsia, Petar Alaupovic et al. · The Journal of Clinical Endocrinology & Metabolism · 2002 · 220 citations · Full text

Medicine, Endocrinology, Pharmacology +13

Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial

Arun J. Sanyal, Patricia López, Eric Lawitz et al. · Nature Medicine · 2023 · 163 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10